ArticleFuture oncology (London, England)2025

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

Maximilian Marhold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.